TITLE

WHO's use of generic antiretrovirals needs support

PUB. DATE
March 2005
SOURCE
PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies against the enforcement of high standards of bioequivalence; Statement issued by physician Mark A. Wainber regarding the program.
ACCESSION #
16605678

 

Related Articles

  • Scaling Up Treatment – Why We Can't Wait. Kim, Jim Yong; Gilks, Charlie // New England Journal of Medicine;12/1/2005, Vol. 353 Issue 22, p2392 

    The article presents the author's views on antiretroviral treatment programs for people living with the human immunodeficiency virus (HIV) and AIDS. HIV infection has largely become a manageable, chronic condition in countries rich in resources because of the availability of combination-drug...

  • HIV guideline changes could slow virus spread.  // New Scientist;12/5/2009, Vol. 204 Issue 2737, p7 

    The article reports on the advice issued by the World Health Organization (WHO) to administer antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) earlier in the infection cycle. WHO suggests that ART be started when the levels of CD4 immune cells decreased below 200...

  • Antiretroviral access increased but still room for improvement.  // PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p26 

    According to the latest report issued by the WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of patients with HIV infections in low and middle income countries who are receiving antiretroviral (ART) treatments has increased from 400 000 in December 2003 to 1.3 million...

  • Burden, Determinants, and Pharmacological Management of Hypertension in HIV-Positive Patients and Populations: A Systematic Narrative Review. Anh Nguyen, Kim; Peer, Nasheeta; Mills, Edward J.; Pascal Kengne, Andre // AIDS Reviews;Apr-Jun2015, Vol. 17 Issue 2, p83 

    Hypertension among HIV-positive populations has emerged as a new threat to the health and well being of people living with HIV, particularly among those receiving antiretroviral therapy. We reviewed the global evidence on the burden of disease (including prevalence and incidence), determinants...

  • Influence of anti-retroviral therapy on the main spheres of vital activity of HIV affected people. Ulyukin, I. M. // Vestnik Sankt-Peterburgskogo universiteta, Seriia 7: Geologia, G;2013, Issue 2, p240 

    134 HIV-infected young adults were examined by using the Russian version of the "World Health Organization Quality of Life Survey (WHOQOL-100)" technique in order to study the influence of the anti-retroviral therapy on the main domains of vital activity of HIV-affected people. The stages of...

  • HIV Drug Resistance Early Warning Indicators in Namibia with Updated World Health Organization Guidance. Jonas, Anna; Sumbi, Victor; Mwinga, Samson; DeKlerk, Michael; Tjituka, Francina; Penney, Scott; Jordan, Michael R.; Desta, Tiruneh; Tang, Alice M.; Hong, Steven Y. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: In response to concerns about the emergence of HIV drug resistance (HIVDR), the World Health Organization (WHO) has developed a comprehensive set of early warning indicators (EWIs) to monitor HIV drug resistance and good programme practice at antiretroviral therapy (ART) sites....

  • Factors influencing global antiretroviral procurement prices. Wirtz, Veronika J.; Forsythe, Steven; Valencia-Mendoza, Atanacio; Bautista-Arredondo, Sergio // BMC Public Health;2009 Supplement 1, Vol. 9, Special section p1 

    Background: Antiretroviral medicines (ARVs) are one of the most costly parts of HIV/AIDS treatment. Many countries are struggling to provide universal access to ARVs for all people living with HIV and AIDS. Although substantial price reductions of ARVs have occurred, especially between 2002 and...

  • Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Larru, Beatriz; Eby, Jessica; Lowenthal, Elizabeth D. // Pediatric Health, Medicine & Therapeutics;2014, Vol. 5, p29 

    Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), used for the treatment of human immunodeficiency virus (HIV)-1 infection. Approved by the US Food and Drug Administration in 1998, its indication was recently extended to include children as young as 3 months of age. The...

  • The Global Status of HIV Drug Resistance: Clinical and Public-Health Approaches for Detection, Treatment and Prevention. Hong, Steven Y.; Nachega, Jean B.; Kelley, Karen; Bertagnolio, Silvia; Marconi, Vincent C.; Jordan, Michael R. // Infectious Disorders - Drug Targets;Apr2011, Vol. 11 Issue 2, p124 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics